WAF-1 (p21) and p53 polymorphisms in breast cancer.
Keshava-CKC; Frye-BL; Wolff-MS; Weston-A
Proceedings of the 91st Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 1-5, 2000, Philadelphia, PA: American Association for Cancer Research, 2000 Mar; 41:129
Previous studies have indicated that certain p53 polymorphisms confer an increased risk of breast cancer (ORs and 95% CIS = 2.9, 1.4 - 6.3 Carcinogenesis 17: 1313, 1996; 2.5, 1.3 - 4.8 Cancer Epidemiology, Biomarkers and Prevention 6: 105, 1997; 1.5, 1.1 - 2.0, Anticancer Research 18: 2095, 1998). p53 is a transcription factor for Waf-1/p21 a cyclin-dependent kinase inhibitor, which is also polymorphic. To test the hypothesis that minor variants (F = 0.10 Caucasians, 0.27 Latinas, 0.34 African Americans) of a codon 31 polymorphism of Waf-1 are involved in this process, genotypes were determined by PCR/RFLP for 355 women (122 cases and 233 controls) enrolled in breast cancer case-control study. No increased breast cancer risk was associated with inheritance of minor variants of Waf-1 (OR = 1.1, 95% Cl = 0.7 - 1.6). Similarly, analysis by both race and menopausal status was unable to find any association. Finally, despite an increased risk for Caucasians associated with the p53 genotype (CEBP 1997), no risk was found to be associated with Waf-1 alleles independently or in combination with p53 alleles (OR = 1.1, 95Cl = 0.3 - 4.7).
Breast-cancer; Cancer; Cancer-rates; Demographic-characteristics; Racial-factors; Risk-factors; Risk-analysis; Case-studies; Age-factors; Sex-factors
Abstract; Conference/Symposia Proceedings
Proceedings of the 91st Annual Meeting of the American Association for Cancer Research